首页> 美国卫生研究院文献>Diabetes Care >Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin

【2h】

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin

机译：在二甲双胍控制不充分的2型糖尿病中利西拉来每日一次与艾塞那肽每天两次的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

OBJECTIVETo compare efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled with metformin.

机译：目的比较利西拉来每天两次与艾塞那得每天两次在用二甲双胍控制不充分的糖尿病中的疗效和安全性。

著录项

期刊名称 Diabetes Care
作者
Julio Rosenstock; Denis Raccah; László Korányi; Laura Maffei; Gabor Boka; Patrick Miossec; John E. Gerich;
展开▼
作者单位

展开▼
年(卷),期 2013(36),10
年度 2013
页码 2945–2951
总页数 7
原文格式 PDF
正文语种
中图分类护理学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). [J] . Julio Rosenstock, Denis Raccah, László Korányi, Diabetes care . 2013,第10期

机译：在二甲双胍控制不充分的2型糖尿病中，每天一次利西拉来和每日两次艾塞那肽的疗效和安全性：一项为期24周，随机，开放标签，主动对照的研究（GetGoal-X）。
2. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial [J] . Jabbour Serge A., Frias Juan P., Hardy Elise, Diabetes care . 2018,第10期

机译：Exenatide每周一次的安全性和疗效加上Dapagliflozin每日一度，并且单独服用exenatide或Dapagliflozin，患有2型糖尿病的患者与二甲双胍单疗法不充分控制：52周的持续时间-8随机对照试验
3. Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M). [J] . Bo Ahrén, Aniceto Leguizamo Dimas, Patrick Miossec, Diabetes care . 2013,第9期

机译：二甲双胍（GetGoal-M）控制不佳的2型糖尿病的利西拉来每日一次早晨或晚上注射的疗效和安全性。
4. Comparing artificial pancreas controlled by hybrid "closed-loop" machine learning (ML) trained algorithm to multi-daily injection (MDI), insulin pump without CGM and "sensor assisted" insulin pump therapies for Diabetes Type 1 (DT1) treatment [C] . Joan Carles Peiró International Conference on Data Analytics for Business and Industry: Way Towards a Sustainable Economy . 2020

机译：将通过混合“闭环”机器学习（ML）控制的人工胰腺培训算法对多日注于多日注射（MDI），胰岛素泵而没有CGM和“传感器辅助”胰岛素泵疗法1型（DT1）处理
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial [O] . Serge A. Jabbour, Juan P. Frías, Elise Hardy, 2018

机译：二甲双胍单药治疗不能完全控制的2型糖尿病患者艾塞那肽每周一次加艾达那列或每日一次与艾塞那肽或达格列净相比的安全性和有效性：DURATION-8随机对照试验52周的结果
7. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X) [O] . J. Rosenstock, D. Raccah, L. Koranyi, 2013

机译：Lixisenatide每日疗效和安全性与丁肽每天两次在二甲双胍上不充分控制的2型糖尿病：24周，随机，开放标签，主动控制的研究（GetGoal-X）

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅